1. Medtech Insight
  2. >>Leadership
  3. >>Interviews

OneCell Diagnostics’ Mohan Uttarwar Discusses Liquid Biopsy Breakthroughs And The Future Of Precision Oncology

Firm Co-Founder Outlines How Science Meets Scale In Second Part Of The Interview

 
• By Shubham Singh

OneCell’s co-founder Uttarwar discusses clinical validation milestones, CLIA certification, and the startup’s strategic roadmap – from hospital partnerships in India to biopharma collaborations in the US.

As the company gears up for its presence at AACR 2025, this part of the discussion provides a revealing look at the intersection of science, startup execution, and the evolving business of cancer diagnostics.
Key Takeaways

· OneCell has received its CLIA certification in the US and is pursuing CAP and FDA 510(k) pathways, aiming to scale its lab-developed tests without delaying commercial traction.

· With partnerships across 20+ hospitals and hundreds of oncologists in India, OneCell is now targeting Southeast Asia and Africa, and building automated systems for broader reach.

· Backed by a globally trained team and strategic investors, the company is balancing deep scientific R&D with scalable operations and strategic biopharma collaborations.

In the second half of the Medtech Insight’s interview, Mohan Uttarwar, co-founder and CEO of OneCell Diagnostics, dive deeper into the commercial challenges and strategic roadmap for scaling precision oncology...

Uttarwar expands on how OneCell is navigating regulatory pathways, its plans for real-world validation of its AI-powered cancer recurrence tools and why building trust with oncologists and patients is central...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Interviews

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By Marion Webb

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.

Califf Warns Progress May Be In Danger Due To ‘Decimated’ FDA Staff

 
• By Barnaby Pickering

In Vivo spoke to the previous commissioner of the US FDA about recent ongoings at the agency, and where he believes policy should be directed for patient and industry benefit.

Axoft Starts Commercializing Soft BCI-Enabling Materials For R&D Use, Aims To Rewrite BCI Playbook

 
• By Marion Webb

After publishing encouraging results from first-in-human trials of its brain-computer interface, Axoft announced plans to sell its BCI-enabling material Fleuron to researchers and private organizations for R&D use. The company sees this as a revenue stream and feedback loop to refine its BCI platform designed for safer, longer-lasting brain implants.

‘Pathologists Are Hungry For AI-Enabled Digital Pathology’

 
• By Natasha Barrow

Digital pathology makes it possible to unlock insights previously hidden to the human eye, “reshaping how we diagnose and treat patients,” said Nathan Buchbinder, co-founder and chief strategy officer at Proscia. He shared his views on the future of digital pathology and the lessons he has learned from working with pathologists.

More from Medtech Insight